Lintuzumab-gelonin conjugate

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameLintuzumab-gelonin conjugate

Drug Alias NameHuM195/rGelHum-195/rGelAnti-CD33 monoclonal antibody M195-gelonin conjugateGelonin-lintuzumab conjugateAnti-CD-33 Immunotoxin Hum-195/rGel +[6]

ClassificationBiologics > Blood components

Mechanisms of ActionMyeloid cell surface antigen CD33 inhibitorsProtein biosynthesis inhibitors

TargetsMyeloid cell surface antigen CD33

Therapy Area/IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, AcuteLeukemia, Myelogenous, Chronic

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesThe University Of Texas MD Anderson Cancer Center

China Registration ClassN/A

Develop Information

Active CompaniesThe University Of Texas MD Anderson Cancer Center

Inactive CompaniesN/A

Active IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, AcuteLeukemia, Myelogenous, Chronic

Inactive IndicationsN/A

Other Information

ATC CodeN/A